Stockchase Opinions

Colin Stewartdentalcorp HoldingsDNTL.TOBUYJul 11, 2025

Steady business. Purely domestic in Canada. Well run. Growing steadily organically and through acquisition. Biggest in Canada, but only 4-5% market share so lots of room to grow. Scale gives them synergies in tech and in purchasing equipment and supplies. Undemanding multiple at 9x EBITDA, big discount to US names. Could be acquisition target at some point.

$8.10

Stock price when the opinion was issued

$11.00

As of Jan 16, 2026. Market Open.

Healthcare
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

PARTIAL BUY

It rolls up individual dental practices and is the largest provider in Canada. He is starting to accumulate shares in their Canadian funds. It is a safe, conservative and low growth industry. He is hoping to see cash flow grow 10 to 15% annually. It declared a recent dividend of 1 to 1 1/2% and is getting leverage down. Dental practices that sell to Dentalcorp receive shares and become employees of the company. It is a good model of efficiency.

TOP PICK

It owns 570 dental practices and there are 15 000 in Canada. They are looking at how many they want to deal with and acquire, about 150. It should grow organically through cash flow and cost control. It is easily the largest dental practice company in Canada and has initiated a new dividend with a good increase in cash flows. They have debt from acquiring practices and lower interest rates would be good for that debt.       Buy 10  Hold 0  Sell 0

(Analysts’ price target is $12.73)
BUY

We're in a macro environment where small caps are just not doing well; people are just selling and not looking at the underlying businesses. Will work out slowly over time if you hold for 5 years.

WAIT

IT is pretty cheap and he has been looking at it but there is a lot of debt. He would buy if the debt gets to where it is less than three years of cash flow. Pretty strong execution.

RISKY

Good business that is defensive. However, debt levels high - has grown thorough debt. Would recommend watching. EBITDA would suggest company is cheap - however a true analysis of the business would suggest interest rates are a burden. Would recommend investing if the debt levels fall. 

BUY ON WEAKNESS
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research.

DNTL is still getting into its acquisition and roll-out strategy, and currently trades at an OK valuation. 
The company has a strong equity position of $1.8 billion on a $1.6B market cap, although $2.1B of its assets are in goodwill, which can change quickly if an impairment charge takes place. 
Revenue growth has been averaging in the 20%+ range, and it generates positive free cash flows which is mostly puts towards acquisitions. 
We would like to see the company maintain or grow its current sales growth rates, and increase its profitability before stepping in here, but largely the company is on a decent trajectory.  
Unlock Premium - Try 5i Free

BUY ON WEAKNESS

Fantastic business, but high debt levels recently.
Currently going through a strategic review process.
Expecting a private equity business to purchase company.
Strong management team.

BUY
Their future looks strong. They've been acquiring dental offices of various sizes. The costs of dental track inflation, so there is increased revenues from this sector. People need their teeth to be look after regularly, so dental won't be impacted much by a recession. However, interest rates do pressure this sector. DNTL has lots of runway in Canada as well as the U.S, to expand.
WATCH
He's looking at it. They have a roll-up strategy integrating software across many facilities. He wonders if there are too many dental offices around. Also, it's a recent IPO, so he wants to see how they execute their roll-up strategy for a year or two.
WEAK BUY
He likes the repeatability of the business. Pretty good model of what its rate of return will be. Accounting is new and will take a couple of years to sort out. The pandemic didn't help its revenue. He's looking for stable cashflow in the underlying business.
TOP PICK
Trying to consolidate all dental practices in Canada. Acquiring story, so it's kind of a growth story. Underlying business is solid. Hit in pandemic, but recession-proof and ROE is quite high. Moving into orthodontics. No dividend. (Analysts’ price target is $19.56)
BUY

AND does drug distribution in western Canada. Incredibly stable business with good runway for growth. Nice compliment to a portfolio without expensive or risky plays. DNTL rolls up dental practices in Canada. A recession proof business.